4Vianell N, Galli M, De - IVOa. Efficacy and safety of splenec-tomy in immune thrombocytopnic purpura: long - term results of 402 cases [J] . Haematobgica, 2005, 90:72-77. 被引量：1
7Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol, 2003; 21: 1278-1284 被引量：1
9Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol, 2001; 19:2153-2146 被引量：1
10Hainsworth JD, Litchy S, Barton JH, et al. Single agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase Ⅱ trial of the minnie pearl cancer research network. J Clin Oncol, 2003; 21:1746-1751 被引量：1
7Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is ac- tive in adults patients with idiopathic thrombocytopenic purpura [ J ]. Haematologica, 2008,9 ( 93 ) : 930 -933. 被引量：1
8Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receive- ing B cell-depleting therapy with rituximab[ J]. Blood ,2008,1 ( 112 ) : 1147-1150. 被引量：1
9Patnaik A, Mishra SS, Senapati SB, et al. Management of chronic subdural haematoma in a case of idiopathic thrombocytopenic purpura[J]. J Surg Tech Case Rep, 2012,4(2) :132-134. 被引量：1
10Michel Delforge,Vicky Raets,Victor Van Duppen,Marc Boogaerts.??Amifostine does not preferentially stimulate the growth of residual polyclonal progenitor cells in myelodysplastic syndromes(J)Leukemia Research . 2002 (7) 被引量：1
